利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.035 秒)

    Certain 6,7,8,9-tetrahydropyrido[1,2-.alpha.]indoles and their use for the treatment of cerebrovascular disorders
    12.
    发明授权
    Certain 6,7,8,9-tetrahydropyrido[1,2-.alpha.]indoles and their use for the treatment of cerebrovascular disorders 失效
    某些6,7,8,9-四氢吡啶并[1,2-α]吲哚及其用于治疗脑血管障碍的用途

    公开(公告)号：US4987137A

    公开(公告)日：1991-01-22

    申请号：US341380

    申请日：1989-04-20

    申请人： Dagmar Hoeltje ,  Dietrich Thielke

    发明人： Dagmar Hoeltje ,  Dietrich Thielke

    IPC分类号： A61K31/435 ,  A61K31/445 ,  A61K31/535 ,  A61P9/00 ,  A61P25/28 ,  C07D471/04

    CPC分类号： C07D471/04

    摘要： A compound of formula (I) or a pharmaceutically acceptable salt thereof; ##STR1## wherein: R.sub.1 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or halogen;R.sub.2 and R.sub.3 are both hydrogen or together represent a bond;R.sub.4 is hydrogen and R.sub.5 is hydrogen or R.sub.4 and R.sub.5 together represent an oxo group;R.sub.6 is C.sub.1-7 alkyl substituted by NR.sub.8 R.sub.9 where R.sub.8 and R.sub.9 are independently hydrogen or C.sub.1-4 alkyl or together are C.sub.3-7 polymethylene optionally containing a further heteroatom which is oxygen, sulphur or nitrogen substituted by R.sub.10 where R.sub.10 is hydrogen, C.sub.1-4 alkyl or benzyl, and optionally substituted by one or two C.sub.1-4 alkyl, C.sub.2-5 alkanoyl, C.sub.1-4 alkoxycarbonyl, aminocarbonyl optionally substituted by one or two C.sub.1-6 alkyl groups or by a benzyl group, cyano, phenyl or benzyl and wherein any phenyl or benzyl group is optionally substituted in the phenyl ring by one or two halo, CF.sub.3, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, cyano or nitro groups; andR.sub.7 is hydrogen or C.sub.1-4 alkyl.

    Aminoalkyl secocanthine derivatives and their use
    13.
    发明授权
    Aminoalkyl secocanthine derivatives and their use 失效
    氨基烷基蛇黄素衍生物及其用途

    公开(公告)号：US4835271A

    公开(公告)日：1989-05-30

    申请号：US879057

    申请日：1986-06-26

    申请人： Dagmar Hoeltje ,  Dietrich Thielke

    发明人： Dagmar Hoeltje ,  Dietrich Thielke

    IPC分类号： A61K31/435 ,  A61K31/445 ,  A61K31/535 ,  A61P9/00 ,  A61P25/28 ,  C07D471/04

    CPC分类号： C07D471/04

    摘要： A compound of the formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein: R.sub.1 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or halogen;R.sub.2 and R.sub.3 are both hydrogen or together represent a bond;R.sub.4 is hydrogen and R.sub.5 is hydrogen or R.sub.4 and R.sub.5 together represent an oxo group;R.sub.6 is C.sub.1-7 alkyl substituted by NR.sub.8 R.sub.9 where R.sub.8 and R.sub.9 are independently hydrogen or C.sub.1-4 alkyl or together are C.sub.3-7 polymethylene optionally containing a further hetereoatom which is oxygen, sulphur or nitrogen substituted by R.sub.10 where R.sub.10 is hydrogen, C.sub.1-4 alkyl or benzyl, and optionally substituted by one or two C.sub.1-4 alkyl, C.sub.2-5 alkanoyl, C.sub.1-4 alkoxycarbonyl, aminocarbonyl optionally substituted by one or two C.sub.1-6 alkyl groups or by a benzyl group, cyano, phenyl or benzyl and wherein any phenyl or benzyl group is optionally substituted in the phenyl ring by one or two halo, CF.sub.3, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, cyano or nitro groups; andR.sub.7 is hydrogen or C.sub.1-4 alkyl.

    摘要翻译： 式（I）的化合物或其药学上可接受的盐：其中：R 1是氢，C 1-6烷基，C 1-6烷氧基或卤素; R2和R3都是氢或一起代表键; R4是氢，R5是氢或R4和R5一起代表氧基; R6是被NR8R9取代的C1-7烷基，其中R8和R9独立地是氢或C1-4烷基，或者一起是C3-7聚亚甲基，任选地含有另外的羟基取代基，它是由R10取代的氧，硫或氮，其中R10是氢，C1- 烷基或苄基，并且任选地被一个或两个C 1-4烷基，C 2-5烷酰基，C 1-4烷氧基羰基，任选被一个或两个C 1-6烷基取代的氨基羰基或苄基，氰基，苯基或苄基 并且其中任何苯基或苄基在苯环中任选被一个或两个卤素，CF 3，C 1-4烷基，C 1-4烷氧基，氰基或硝基取代; 并且R 7是氢或C 1-4烷基。

    Pyrido[1,2-a]indoles and their use as CNS agents
    18.
    发明授权
    Pyrido[1,2-a]indoles and their use as CNS agents 失效
    吡啶并[1,2-a]吲哚及其用作CNS剂

    公开(公告)号：US4968699A

    公开(公告)日：1990-11-06

    申请号：US135837

    申请日：1987-12-21

    申请人： Dagmar Hoeltje ,  Ljerka Jozic ,  Dietrich Thielke

    发明人： Dagmar Hoeltje ,  Ljerka Jozic ,  Dietrich Thielke

    IPC分类号： A61K31/435 ,  C07D471/04

    CPC分类号： C07D471/04 ,  A61K31/435

    摘要： A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein: R.sub.1 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or halogen;R.sub.2 and R.sub.3 are both hydrogen or together represent a bond;R.sub.4 is hydrogen and R.sub.5 is hydrogen or R.sub.4 and R.sub.5 together represent an oxo group;R.sub.6 is phenyl C.sub.1-7 alkanoyl in which the phenyl moiety is optionally substituted by one or two of halogen, nitro, meta- or para-methoxy, methyl or NR.sub.8 R.sub.9 wherein R.sub.8 and R.sub.9 are independently hydrogen or C.sub.1-6 alkyl or R.sub.8 and R.sub.9 together are C.sub.2-6 polymethylene, or 3,4-disubstituted by methylenedioxy or ethylenedioxy; or C.sub.1-7 alkanoyl substituted by NR.sub.10 R.sub.11 where R.sub.10 and R.sub.11 are independently hydrogen or C.sub.1-4 alkyl or together are C.sub.3-7 polymethylene optionally containing a further heteroatom which is oxygen, sulphur or nitrogen substituted by R.sub.12 where R.sub.12 is hydrogen, C.sub.1-4 alkyl or benzyl, and optionally substituted by one or two C.sub.1-4 alkyl, C.sub.2-5 alkanoyl, C.sub.1-4 alkoxycarbonyl, aminocarbonyl optionally substituted by one or two C.sub.1-6 alkyl groups or by a benzyl group, cyano, phenyl or benzyl and wherein any phenyl or benzyl group is optionally substituted in the phenyl ring by one or two halo, CF.sub.3, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, cyano or nitro groups; andR.sub.7 is hydrogen or C.sub.1-4 alkyl;and a pharmaceutically acceptable carrier.